NCT04949906

Study on Yangxue Nao Granules Reducing the Risk of Stroke

A Real World Study of Yangxuenao Granules Reducing Bleeding Risk in Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 150 (actual)
• Sponsor: Peking University Third Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

Objective: To explore the effectiveness of raising serum nao granules in reducing the risk of bleeding in patients with acute ischemic stroke treated with intravenous thrombolysis in the real world

Detailed description

Objective: To explore the effectiveness of raising serum nao granules in reducing the risk of bleeding in patients with acute ischemic stroke treated with intravenous thrombolysis in the real world Study Design. This study was a single center real world study. Through the review data, this study included in January 1, 2017 to September 30, 2019, see a doctor at Peking University third hospital neurology, emergency diagnosis of acute ischemic stroke, and venous thrombolysis in patients with a queue, on the basis of whether the application have serum brain particles are divided into a group and the control group, serum application parameters and nonparametric comparison, K-M curve and Cox regression model were used to evaluate the effectiveness of Yangxuenao granules in reducing bleeding conversion after intravenous thrombolysis by comparing the number of microbleeding, stroke severity score and modified Rankin score after 3 months follow-up with the weighted craniocerebral magnetic sensitivity imaging sequence reexamined within 48 hours.

Conditions

• Cerebral Infarction

Interventions

Type	Name	Description
DRUG	Raise serum brain granules	Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke
DRUG	No nourishing serum brain granules are used	No nourishing serum brain granules are used

Timeline

• Start date: 2019-06-01
• Primary completion: 2020-09-01
• Completion: 2020-11-01
• First posted: 2021-07-02
• Last updated: 2021-07-06

Locations

1 site across 1 country: China